Cargando…

Efficacy of a single injection of brolucizumab in neovascular age-related macular degeneration on visual acuity and micromorphometry

PURPOSE: To assess short-term efficacy of a single injection of brolucizumab in neovascular AMD. METHODS: This was a multicenter, retrospective chart review of 25 eyes of 25 patients who received a single injection of brolucizumab. Visual acuity (VA) and optical coherence tomography (OCT) features s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Joshi, Shrinivas, Verma, Lalit, Ayachit, Guruprasad, Salvi, Rajashree, Asad, Yusra, Gupta, Avnindra, Patil, Anuja, Ayachit, Apoorva
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683673/ https://www.ncbi.nlm.nih.gov/pubmed/37787238 http://dx.doi.org/10.4103/IJO.IJO_210_23

Ejemplares similares

Commentary: Macular hole surgery – A tweak here and there
por: Vibhute, Giriraj, et al.
Publicado: (2022)

Commentary: Multicolor imaging in optic disc swelling
por: Ayachit, Apoorva, et al.
Publicado: (2017)

Validating the pachychoroid disease spectrum using multimodal imaging
por: Ayachit, Guruprasad, et al.
Publicado: (2018)

Response to comment on: Validating the pachychoroid disease spectrum using multimodal imaging
por: Ayachit, Guruprasad, et al.
Publicado: (2019)

Choroidal caverns in pachychoroid neovasculopathy
por: Ayachit, Apoorva, et al.
Publicado: (2020)

Commentary on vitrectomy without encircling band for rhegmatogenous retinal detachment with inferior break utilizing 3D heads up viewing system
por: Joshi, Shrinivas, et al.
Publicado: (2021)

Big data and artificial intelligence - Tools to be future ready?
por: Joshi, Shrinivas, et al.
Publicado: (2021)

Commentary: A questionnaire-based assessment of Safe Eye Examination (SEE) technique
por: Joshi, Shrinivas, et al.
Publicado: (2021)

Commentary: 3D heads-up surgeries: Backing our backs, and necks!
por: Joshi, Shrinivas, et al.
Publicado: (2022)

Commentary: Dexamethasone and dilemma
por: Joshi, Shrinivas, et al.
Publicado: (2022)

A rare case of unilateral diffuse melanocytic proliferation
por: Ayachit, Guruprasad, et al.
Publicado: (2018)

Commentary: Rickettsial retinitis – Direct bacterial infection or an immune-mediated response?
por: Ayachit, Apoorva, et al.
Publicado: (2017)

Response to comment on: A rare case of unilateral diffuse uveal melanocytic proliferation
por: Ayachit, Guruprasad, et al.
Publicado: (2018)

Commentary: Neuroretinitis, frosted branch angiitis and paracentral acute middle maculopathy in a young female
por: Ayachit, Apoorva, et al.
Publicado: (2020)

Brolucizumab for Neovascular Age-Related Macular Degeneration (BEL Study)
por: Van Cleemput, Liesbeth, et al.
Publicado: (2023)

Brolucizumab for macular degeneration
Publicado: (2020)

Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
por: Yannuzzi, Nicolas A, et al.
Publicado: (2019)

Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD)
por: Sharma, Ashish, et al.
Publicado: (2020)

The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
por: Musiał-Kopiejka, Magdalena, et al.
Publicado: (2022)

Choroidal osteoma with choroidal neovascular membrane: Successful treatment with intravitreal bevacizumab
por: Pandey, Neeraj, et al.
Publicado: (2010)

Smokestack leak on indocyanine green angiography in acute central serous chorioretinopathy
por: Ayachit, Apoorva, et al.
Publicado: (2018)

Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye
por: Maggio, Emilia, et al.
Publicado: (2022)

The effect of intravitreal brolucizumab on choroidal thickness in patients with neovascular age-related macular degeneration
por: Bae, Ki Woong, et al.
Publicado: (2022)

Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects
por: Garweg, Justus G., et al.
Publicado: (2023)

Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map
por: Khanani, Arshad M., et al.
Publicado: (2021)

Brolucizumab for persistent macular fluid in neovascular age-related macular degeneration after prior anti-VEGF treatments
por: Hussain, Rehan M., et al.
Publicado: (2021)

Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study
por: Chakraborty, Debdulal, et al.
Publicado: (2021)

Brolucizumab in Pretreated Neovascular Age-Related Macular Degeneration: Case Series, Systematic Review, and Meta-Analysis
por: Hänsli, Christof, et al.
Publicado: (2023)

Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis
por: Yu, Justin S, et al.
Publicado: (2021)

One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
por: Matsumoto, Hidetaka, et al.
Publicado: (2022)

Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
por: Matsumoto, Hidetaka, et al.
Publicado: (2023)

Evaluation of cardiac parameters and other safety outcomes of brolucizumab treatment in patients with neovascular age‐related macular degeneration
por: Zakaria, Nadia, et al.
Publicado: (2022)

First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration
por: Abdin, Alaa Din, et al.
Publicado: (2022)

A CONSENSUS ON RISK MITIGATION FOR BROLUCIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Patient Selection, Evaluation, and Treatment
por: Holz, Frank G., et al.
Publicado: (2022)

Real-world study to evaluate the efficacy and safety of intravitreal brolucizumab for refractory neovascular age-related macular degeneration
por: Yeom, Hoseok, et al.
Publicado: (2023)

Commentary: Impact of COVID-19 pandemic on income and opportunities of ophthalmologists in India. Ophthalmologists’ Workplace Expectations and Satisfaction Survey (OWESS) Report 1
por: Joshi, Shrinivas, et al.
Publicado: (2021)

Morphological Macular Changes Under Brolucizumab Treatment for Neovascular Age-Related Macular Degeneration Refractory to Previous Anti-VEGF Treatment Compared with Treatment-Naive Eyes
por: William, Antony, et al.
Publicado: (2023)

Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy
por: Ferrante, Nicola, et al.
Publicado: (2022)

Real-World Experience Using Intravitreal Brolucizumab Alone or in Combination with Aflibercept in the Management of Neovascular Age-Related Macular Degeneration
por: Mehta, Neesurg, et al.
Publicado: (2023)

Real-World Frequency and Management of Ocular Adverse Events in Eyes with Neovascular Age-Related Macular Degeneration Treated with Brolucizumab
por: Zubricky, Ryan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rnfjuhd5gojpgjq4k31egof698